Corporate
-
Regulatory Bodies & Rulings
Marketing
-
Trends
Cipla gets marketing approval on generic Tamiflu
Our Bureau
Mumbai
,
Feb. 9
CIPLA has received marketing approval from the Drug Controller General of India to market the generic version of Tamiflu, the bird-flu drug globally marketed by Roche.
A senior representative with Cipla confirmed the development and said that the chemically similar drug would be priced lower than the branded Tamiflu.
No details were however divulged on whether the company would commence marketing the product in the domestic market.
An analyst tracking the segment said that Cipla would be able to market the drug in India, as there is no patent on the drug here.
Patent applications on the drug are pending in the mailbox of the Patent Controller's office.Cipla also has export orders on generic Tamiflu in its kitty and the first shipment is expected to be sent to an Asian country later this month, the official said. No details were divulged on the size of the order.
The bullish outlook on Cipla is compounded by the fact that the company's board meets on Saturday to discuss a bonus issue
More Stories on :
Regulatory Bodies & Rulings |
Trends |
Pharmaceuticals |
Cipla Ltd
Article
E-Mail
::
Comment
::
Syndication
::
Printer Friendly Page
|
